A Study of ARRY-614 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This is a Phase 1 study during which patients with low or intermediate-1 risk myelodysplastic
syndrome (MDS) will receive investigational study drug ARRY-614.
This study has 2 parts. In the first part, patients will receive increasing doses of study
drug, given either with food or without food, in order to achieve the highest dose of the
study drug possible that will not cause unacceptable side effects. Approximately 60 patients
from the US will be enrolled in Part 1 (Completed).
In the second part of this study, patients will receive the best dose of study drug, given
either with food or without food, determined from the first part of the study and will be
followed to see what side effects and effectiveness the study drug has, if any, in treating
the cancer. Approximately 40 patients from the US will be enrolled in Part 2 (Completed).
Phase:
Phase 1
Details
Lead Sponsor:
Array BioPharma Array Biopharma, now a wholly owned subsidiary of Pfizer